Enlivex Therapeutics Stock Quote ENLV - Stock Price, News, Charts, Message Board, Trades

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Current Price

1.33

Bid

1.26

Ask

1.37

Volume

83,204

1.23 Day's Range 1.4126

1.15 52 Week Range 4.59

Market Cap

24.736M

Previous Close

1.39

Open

1.39

Last Trade

1.26

Last Trade Time

Financial Volume

$ 114,434

VWAP

1.3753

Average Volume (3m)

61,814

Shares Outstanding

18,598,555

Dividend Yield

PE Ratio

-0.87

Earnings Per Share (EPS)

-1.56

Revenue

Net Profit

-29.07M

Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threate... Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.enlivex.com

Headquarters

Ness Ziona, Center, Isr

Founded

1970

Enlivex Therapeutics Ltd is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ENLV. The last closing price for Enlivex Therapeutics was $1.39. Over the last year, Enlivex Therapeutics shares have traded in a share price range of $ 1.15 to $ 4.59.

Enlivex Therapeutics currently has 18,598,555 shares outstanding. The market capitalization of Enlivex Therapeutics is $25.85 million. Enlivex Therapeutics has a price to earnings ratio (PE ratio) of -0.87.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Enlivex Receives Regulatory Authorization For The Initiation Of A Phase I Clinical Trial To Evaluate Allocetra In Patients With Psoriatic Arthritis

• First study of AllocetraTM in psoriatic arthritis, a chronic inflammatory condition that causes joint pain, swelling and stiffness, affects as many as 30% of people with psoriasis1, and has...

Enlivex Announces the Dosing of the First Patient in a Randomized, Placebo-Controlled Phase I/II Trial Evaluating AllocetraTM in up to 46 Patients with Thumb Osteoarthritis

First patient dosed with AllocetraTM in thumb osteoarthritis, a degenerative, debilitating and progressive disease that affects millions of peopleThumb osteoarthritis currently has no...

Enlivex Announces Positive Interim Data Readout from a Phase I/II Trial Evaluating Allocetra in End-Stage Knee Osteoarthritis

Key Highlights Enrolled patients with severe knee osteoarthritis who were indicated for knee-replacement surgery received a single local injection of AllocetraTM into the knee as a “last...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-0.03	-2.20588235294	1.36	1.46	1.23	48319	1.3948774	CS
4	-0.07	-5	1.4	1.48	1.23	38265	1.3834402	CS
12	-0.3	-18.4049079755	1.63	1.6648	1.18	61814	1.40646917	CS
26	-1.57	-54.1379310345	2.9	4.59	1.15	122955	2.20318075	CS
52	-1.17	-46.8	2.5	4.59	1.15	88739	2.28822446	CS
156	-6.12	-82.1476510067	7.45	13.95	1.15	86019	6.18769595	CS
260	-20.57	-93.9269406393	21.9	44.9	1.15	161595	9.64528786	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
WINTWindtree Therapeutics Inc	$ 8.24 (150.46%)	48.57M
BFIBurgerFi International Inc	$ 0.4206 (97.37%)	313.59M
NBSTWNewbury Street Acquisition Corporation	$ 0.1349 (92.71%)	122.1k
YIBOPlanet Image International Ltd	$ 2.915 (53.43%)	260.07k
CREVCarbon Revolution Public Ltd	$ 9.00 (45.87%)	8.06M
NMHINatures Miracle Holding Inc	$ 0.2035 (-48.06%)	7.69M
TANHTantech Holdings Ltd	$ 0.2585 (-47.23%)	6.75M
DXCMDexCom Inc	$ 64.00 (-40.66%)	53.92M
PSIGPS International Group Ltd	$ 1.42 (-31.40%)	716.26k
POAIPredictive Oncology Inc	$ 1.36 (-27.27%)	6.02M
SLNASelina Hospitality PLC	$ 0.0305 (-18.88%)	408.61M
BFIBurgerFi International Inc	$ 0.4206 (97.37%)	313.59M
NVDANVIDIA Corporation	$ 113.06 (0.69%)	293.33M
SQQQProShares UltraPro Short QQQ	$ 9.10 (-2.88%)	176.49M
SGMOSangamo Therapeutics Inc	$ 0.8612 (28.15%)	123.71M